Objectives. Cytoplasmic inclusions containing TDP-43 are a pathological hallmark of several neurodegenerative disorders, including amyotrophic lateral sclerosis (ALS) and frontotemporal dementia. TDP-43 is an RNA binding protein involved in gene regulation through control of RNA transcription, splicing and transport. However, the function of TDP-43 in the nervous system is largely unknown and its role in the pathogenesis of ALS is unclear. The aim of this study was to identify genes in the central nervous system that are regulated by TDP-43. Methods.
Introduction
Amyotrophic lateral sclerosis (ALS) is characterised by ubiquitinated cytoplasmic, nuclear, and neuritic inclusions in the motor neurons of the brain and spinal cord. The discovery that TDP-43 is a major component of these inclusions (1, 2) was a key breakthrough in the understanding of ALS as it suggests that TDP-43 functions in important neuronal activities, the impairment of which would lead to degeneration of specific neuronal populations. TDP-43 is a heterogeneous nuclear ribonucleoprotein (hnRNP) that is encoded by the TARDBP gene (3) . The discovery of mutations within TARDBP in familial and sporadic ALS patients (4, 5) has established a clear pathogenic link between TDP-43 and ALS. Approximately 40 different TARDBP missense mutations have now been reported in ALS, including three cases of ALS plus concomitant frontotemporal lobar degeneration (6) . However, although TDP-43 has been implicated in a diverse range of metabolic and physiological processes, including RNA transport and splicing, mutations have provided no insight into why motor neurons die in ALS patients.
TDP-43 binds to UG-rich repeats in target RNAs, facilitating mRNA splicing and transport. The ability of TDP-43 to bind RNA, the presence of a nuclear localisation signal, and a strong nuclear export sequence indicate that TDP-43 has a role in nuclear-cytoplasmic shuttling of mRNAs (7) . The observation of TDP-43 within RNA granules in developing brain further suggests that TDP-43 may be involved in mRNA transport (8) . As DNA is confined to the nucleus, appropriate subcellular trafficking of mRNA plays an important role in determining the biological activities of the transcripts, particularly in neurons where the distance between the nucleus and subcellular compartments can be significant. In addition to its role in RNA transport, TDP-43 also regulates splicing by binding to UG-rich sequences within pre-mRNA (9) . Tissue-specific alternative mRNA splicing is essential for the expression of functionally different gene products from a single gene, and various human diseases are known to be caused by disruption of the splicing machinery (10) .
There is increasing evidence that ALS is a disorder of RNA metabolism. RNA oxidation precedes the development of overt motor neuron damage in transgenic mice expressing ALSassociated mutations in superoxide dismutase -1 (SOD1) (11) . Mutations in FUS/TLS, an RNA binding protein with similar structure to TDP-43, have been associated with both frontotemporal dementia (FTD) and ALS (6, 12) . Similarly, mutations in SETX, a DNA/RNA helicase involved in RNA transcription and translation, have been linked with cerebellar ataxia, progressive motor neuropathy and more recently with ALS (6, 13). Another well-established example of altered RNA processing in neurodegeneration is loss of the SMN (survival of motor neuron) RNA binding protein in spinal muscular atrophy, a form of motor neuron disease with earlier onset than ALS (14) . Other ALS-associated genes involved in RNA processing pathways include the ribonuclease protein, angiogenin (ANG) (15) , and elongator protein 3 (ELP3), a component of the RNA polymerase II complex (16).
Even though most ALS patients do not have mutations in TDP-43 (but TDP-43 still forms aggregates) the loss of TDP-43 function and resulting disruption of RNA processing is likely to be a major contributor to the disease. This is supported by the fact that a transgenic mouse overexpressing mutant human TDP-43 does not develop cytoplasmic aggregates and yet motor neurons still degenerate, suggesting that aggregates are not the primary cause of degeneration (17) . Furthermore, knockdown of TDP-43 in Drosophila (18) and zebrafish (19) leads to behavioural motor deficits and abnormal motor neuron morphology. We therefore hypothesise that any dysfunction of TDP-43 (aggregation or mutation) will affect the RNA-binding ability of the protein and the subsequent regulation and processing of RNA transcripts needed for motor neuron function.
An important step in understanding how TDP-43 causes ALS is identifying the RNA transcripts that TDP-43 regulates, followed by the production of a comprehensive map of RNA targets in normal nerve tissue. Recent reports have begun to identify the RNA targets of TDP-43 in the rodent brain, using a combination of RNA-immunoprecipitation followed by either direct sequencing (20) (21) (22) (23) or microarray analysis (24) . In the first report, cultured embryonic rat cortical neurons were used and the 4,352 genes identified were enriched for Gene Ontology terms related to synaptic function, RNA metabolism and neuronal development (20) . In the second study, over 6,300 potential TDP-43 RNA targets were identified in the adult mouse brain Localisation of TDP-43 within axon terminals of the mouse neuromuscular junction was also examined.
Material and Methods

Animals and tissue preparation
Four 10-week-old C57BL/6J mice were euthanased and brain tissue harvested. Mouse brain tissue was homogenised in polysome lysis buffer supplemented with RNase and protease inhibitors as previously described (25) . Following centrifugation at 15,000 x g for 15 minutes at Analysis (IPA) software (Ingenuity Systems, Redwood City, CA). IPA was used to assess the signalling and metabolic pathways, molecular networks, and biological processes that were most significantly represented in the microarray dataset. The MEME suite was used to identify common sequence motifs shared among the binding partners (26) . Gene Ontology (GO) enrichment analysis of the significant transcripts was carried out using FatiGO (27). Supplemental file 3) . The data from the present study was then compared to previous publications (where gene lists were available) to determine the extent of overlap between the TDP-43 target genes identified (Fig 1) .
The genes identified in the present study represent 17. The MEME Suite program (26) was then used to identify common sequence motifs from the 150 most highly enriched (based on fold change) TDP-43 target RNAs. The most common motif identified from the TDP-43 RIP-chip was (TG)n, corresponding to the known (UG)n RNA binding motif of TDP-43 (Fig 2A) . As (TG)n is a common repeat, we also analysed RNA from the IgG control RIP-chip experiment (background "noise" from non-specific binding). The (TG)n repeat motif was not enriched among the RNAs recovered from the IgG control RIP-chip experiment; only an (A)n motif was identified, which corresponds to the mRNA polyA site ( Fig   2B) . The frequency of the (TG)n motif within cDNA sequences was 63%. Of those genes containing a (TG)n motif, the location of the motif was predominantly in the 3'UTR (92%). The second most common motif identified was a CG-rich sequence (Fig 2C) , which was primarily found in the 5'UTR (79%) and may simply reflect the high GC content of the promoter region.
The motif analysis confirms the RIP-chip method is detecting true RNA targets of TDP-43, as the known binding motif (UG)n was the most common sequence detected.
Ingenuity Pathway Analysis of the TDP-43 RNA targets was used to identify biological functions that are potentially regulated by TDP-43. Multiple genes were related to the expected biological functions associated with ALS, including nervous system development and function and neurological disease ( Table 1) Analysis of the immunolabelling revealed that TDP-43 was concentrated presynaptically within the motor nerve terminal, directly opposite postsynaptic acetylcholine receptors (Fig 3) .
The TDP-43 target RNAs related to synaptic function identified in this study are shown in Table   2 , where they have been grouped into seven broad functional categories and overlap with the Sephton et al. (20) study has been highlighted. Thirteen genes from Table 2 were randomly selected for validation in an independent RIP experiment using RT-PCR (Fig 4 and Supplemental file 1), including seven genes associated with synaptic vesicle trafficking (top row of Fig 3) . The gene encoding TDP-43 (Tardbp) was also included, as there is evidence that TDP-43 may be self-regulated. The RT-PCR results confirmed that these RNA targets were enriched in the TDP-43 IP RNA preparation.
Discussion
The RIP-chip analysis of mouse brain tissue provided a list of 1,839 putative RNA targets of TDP-43. The most common sequence detected in the 150 most abundant RNAs was the known TDP-43 binding motif (UG)n (Fig 2) confirming the RIP-chip method was detecting true RNA targets of TDP-43. Of the 1,839 genes identified in mouse brain in this study, 699 (38%) overlapped with those found in rat embryonic cortical neuron cultures (20) . Comparison with other published reports of TDP-43 RNA targets revealed a single gene was common amongst the four studies (Fig 1) . The Arf3 gene encodes a small guanine nucleotide-binding protein that stimulates ADP-ribosyltransferase activity and which also plays a role in vesicular trafficking (28) . The fact that only one gene was common to all studies is most likely due to the different cell/tissue types studied, as well as the fact that the two studies using neuronal cell lines (23, 24) only identified a relatively small number of TDP-43 targets. The Arf3 gene contains a large (TG) 87 repeat in the 3'UTR and the corresponding mRNA has been isolated from cortical axons (29) . Therefore, further investigation of the ARF3 gene and it's protein in ALS and FTD is warranted.
We hypothesise that RNPs such as TDP-43 may be playing a major role in transport of mRNAs along the axonal length for site-specific translation at the synapses, such as the neuromuscular synapse, and are crucial for fine-tuning of synaptic transmission. This proposed role for TDP-43 regulation of local translation is supported by immunohistochemistry demonstrating that TDP-43 is localised to the presynaptic neuromuscular junction in mouse muscle (Fig 3) . In human motor neurons, TDP-43 is found in the nucleus, rough endoplasmic reticulum, mitochondria, and of relevance to this study, in synaptic vesicles of presynaptic terminals of anterior horn neurons (30) . A recent report has also demonstrated that TDP-43 is actively transported in motor neuron axons (31), lending further support to the hypothesis that TDP-43 is involved in transport of RNA for local translation at presynaptic terminals.
The network and gene ontology enrichment analyses conducted in this study, together with the localisation of TDP-43 at the presynaptic membranes (Fig 3) , strongly suggest that TDP-43 may regulate the RNA of genes involved in synaptic transmission. Of particular interest were the number of genes related to synaptic vesicle docking, fusion and exocytosis ( Syntaxin is also decreased in the anterior horn, though to a lesser extent than synaptophysin and synapsin (34) . The decrease in expression of synaptic vesicle proteins in the spinal cord of ALS patients may be due to loss of TDP-43-regulated transport of the RNA coding for these proteins.
TDP-43 has previously been shown to be localised to RNA granules in dendrites of rat hippocampal neurons, and these granules also contain mRNA of known TDP-43 targets (38) .
Axons also contain mRNAs and ribosomes, and are metabolically active in synthesising proteins locally (39). Therefore, loss of TDP-43 mediated transport of synaptic vesicle mRNAs could disrupt both dendritic synapses and the neuromuscular junction.
Another well-established example of altered RNA processing in motor neuron disease is loss of SMN protein in spinal muscular atrophy (SMA) (40) . SMN plays a multifunctional role in ribonucleoprotein metabolism, pre-messenger RNA splicing and RNA transport. In SMA, expression of presynaptic vesicle proteins such as synaptophysin, VAMP and synaptotagmin are decreased (41) and mouse models of SMA show evidence of impaired synaptic vesicle release at neuromuscular junctions (42) . Similarly, impaired synaptic vesicle release, due to loss of TDP-43-mediated transport of synaptic vesicle RNAs, may also result in muscle denervation and loss of motor neuron function in ALS.
Mutations in ubiquitously expressed proteins like TDP-43 and SMN lead to degeneration of motor neurons in the CNS but not other tissues in which these proteins are expressed. Motor neurons may be particularly sensitive to disruptions in mRNA transport, due to their long axon length. Recent work from C. elegans suggests that local presynaptic translation takes place in the mature nervous system, and that regulating this capacity is required for the maintenance of synapse and axon morphology (43) . In human motor neurons, synaptic terminals can be more than a metre removed from the nucleus. Decreased capacity to transport mRNAs into distal processes could jeopardise the ability to respond to injury or local stimuli within axons. In ALS, loss of synapse proteins may be what ultimately leads to motor neuron death.
In this study we have shown that TDP-43 is localised at the presynaptic membrane of axon terminals of the mouse neuromuscular junction, and that over 100 RNA binding targets of TDP-43 are associated with synaptic function. Decreased capacity to transport synaptic mRNAs into distal processes may be one possible mechanism that ultimately leads to motor neuron death in ALS. Future experiments will be necessary to demonstrate co-localisation of identified RNA targets with the TDP-43 protein, within presynaptic terminals of motor neurons. 
